AstraZeneca PLC (AZNCF)
| Market Cap | 224.29B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| Shares Out | n/a |
| EPS (ttm) | 4.97 |
| PE Ratio | 28.86 |
| Forward PE | 15.59 |
| Dividend | 3.10 (2.11%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 379 |
| Average Volume | 875 |
| Open | 144.10 |
| Previous Close | 146.92 |
| Day's Range | 144.10 - 144.10 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.17 |
| RSI | 52.40 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca gets FDA priority review for Imfinzi application
AstraZeneca gets EU backing for eco-friendly inhaler version
AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca Plc (NASDAQ: AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gM...
AstraZeneca succeeds in late-stage trial for myasthenia gravis therapy
AstraZeneca's immune disorder drug succeeds in late-stage trial
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasth...
What's Driving the Market Sentiment Around AstraZeneca?
AstraZeneca's (NYSE: AZN) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 6.81 million shares sold short , which is 0.22% of all regular share...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List
Bloomberg's 50 Companies to Watch leverages catalysts like new leadership, AI, and policy shifts to identify high-potential stocks for 2025. Yield-based 'dogcatcher' analysis spotlights 15 dividend pa...
AstraZeneca investing $50B in US, Trump calls it an 'honor'
British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some credit due to its tariff policy and President T...
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Presi...
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in ... Full story available on Benzinga.com
AstraZeneca to invest US$50B in U.S. by 2030
Jamie Murray, President of The Murray Wealth Group, joins BNN Bloomberg to discuss his outlook on the markets as well as stocks to watch.
5 Things to Know Before the Stock Market Opens
Stock futures are little changed as investors watch for more earnings and trade developments; AstraZeneca (AZN) said it plans to invest $50 billion in U.S. production facilities; Opendoor Technologies...
Trump tariff pressure: AstraZeneca to move production to US, announces $50 billion manufacturing push
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company's expectation t...
AstraZeneca unveils $37 billion US investment plan amid tariff threats
The announcement marks the latest by a global pharmaceutical giant to expand its US footprint. The post AstraZeneca unveils $37 billion US investment plan amid tariff threats appeared first on Premium...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2161185777-2ba3444e8e3d442d86c828820395d0b1.jpg)
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about tariffs loom over the industry.
AstraZeneca pledges $50bn investment in the US amid 200% tariff fears
British-Swedish pharmaceutical company AstraZeneca is expanding its presence in the US in a bid to boost sales in its largest market.
Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP
AstraZeneca begins European exit — will invest $50 billion in the U.S. amid tariff threats
The U.S. is a key market for the pharmaceutical industry. AstraZeneca expects 50 percent of its revenue to come from the U.S. by 2030.
AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’
Also: All the news and watercooler chat from Fortune.
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announci...
AstraZeneca commits $50B to US expansion amid Trump tariff pressure
AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes building its largest-ever manufacturing facility in Virginia and expanding...
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
US President Donald Trump has threatened to impose tariffs of up to 20% on drug imports to boost manufacturing in America and drive down costs.
AstraZeneca pledges $50bn US investment ahead of drugs tariffs
Donald Trump is expected to announce tariffs of up to 200% on drugs makers in August